Clinical Trials Sponsored by Regimmune Inc.

Total 35751 results

Revimmune
Washington University School of Medicine; Amarex Clinical Research

Terminated

InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) (ILIAD-7-US-I)

COVID-19 | Lymphocytopenia

United States
Memorial Sloan Kettering Cancer Center
MedImmune LLC

Completed

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center
AstraZeneca; MedImmune LLC

Withdrawn

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma | Advanced Lung Cancer | Recurrent Nonsmall Cell Lung Cancer
MedImmune LLC
University of Pittsburgh; Passport Health

Completed

Assessing Choice in the Employer Setting (ACES) Study (MA181)

Healthy

United States
Mt. Sinai Medical Center, Miami
MedImmune LLC

Completed

Subcutaneous Amifostine Safety Study

Lymphoma | Head and Neck Cancer | Lung Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Revimmune

Withdrawn

Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation

Umbilical Cord Blood Transplant
Angimmune LLC
James Graham Brown Cancer Center

Unknown

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Stage IV Melanoma

United States
Royal Marsden NHS Foundation Trust
Eli Lilly and Company; AstraZeneca; Clovis Oncology, Inc.; MedImmune LLC

Recruiting

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial (PLATFORM)

Adenocarcinoma of the Stomach | Adenocarcinoma of the Oesophagus | Adenocarcinoma of the Gastro-oesophageal Junction

United Kingdom
Washington University School of Medicine
NeoImmune Tech

Withdrawn

Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)

COVID-19 | SARS-CoV-2
Washington University School of Medicine
MedImmune LLC

Withdrawn

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (PIVOT-RCC)

Renal Cell Carcinoma
University of Alabama at Birmingham
MedImmune LLC

Withdrawn

Radiation With Chemotherapy and a Study Drug to the Para-Aortic Nodes in Cervical Cancer

Cervical Cancer

United States
Ludwig Institute for Cancer Research
Boehringer Ingelheim; MedImmune LLC; PharmaJet, Inc.; CureVac; Cancer Research Institute...

Completed

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

NSCLC | Metastatic Non-small Cell Lung Cancer

United States
MedImmune LLC
PRA Health Sciences; Cambridge Antibody Technology

Terminated

A Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 in Subjects With Asthma

Asthma

Netherlands, United Kingdom, Australia, Germany, Poland
MedImmune LLC
Department of Health and Human Services

Completed

A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults (MI-CP215)

Healthy

United States
The Oregon Clinic
Bristol-Myers Squibb; MedImmune LLC

Unknown

Selective Dose Escalation for Esophageal Cancer

Esophageal Cancer

United States
M.D. Anderson Cancer Center
Novartis; AstraZeneca; MedImmune LLC

Completed

Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer

Colorectal Cancer | Colon Cancer | Malignant Neoplasms of Digestive Organs

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer

Metastatic Colorectal Cancer

United States
Mohan Suntharalingam
MedImmune LLC

Completed

EVALUATION OF AMIFOSTINE FOR MUCOSAL AND HEMOPOETIC PROTECTION AND CARBOPLATIN, TAXOL, RADIOTHERAPY IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK CANCER.(GCC 0202)

Head and Neck Cancer

United States
MedImmune LLC
Department of Health and Human Services

Completed

A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age (MI-CP217)

Influenza

United States
Revimmune
Washington University School of Medicine; Vanderbilt University School of Medicine

Completed

A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-B)

Severe Sepsis With Septic Shock

United States
Mayo Clinic
Merck Sharp & Dohme LLC; NeoImmune Tech

Recruiting

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma, IDH-Wildtype | Recurrent Gliosarcoma | High Grade Astrocytic Tumor

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Active, not recruiting

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Thyroid Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; MedImmune LLC

Completed

Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Jan Kluytmans
MedImmune LLC; Universiteit Antwerpen

Completed

Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU (ASPIRE-ICU)

Pneumonia | Nosocomial Pneumonia | Pneumonia, Ventilator-Associated

Netherlands
University of Texas Southwestern Medical Center
MedImmune LLC

Withdrawn

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

Diabetic Foot Ulcer

United States
The Dale & Frances Hughes Cancer Center
MedImmune LLC

Completed

Toxicities Associated With Subcutaneous Administration of Ethyol (Amifostine) for the Prevention of Radiation-Induced Toxicities

Head and Neck Cancer | Lung Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
Northwestern University
National Cancer Institute (NCI); AstraZeneca; MedImmune LLC

Completed

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Malignant Glioma | Recurrent Glioblastoma

United States
MedImmune LLC
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

Coronary Artery Disease | Atherosclerosis

United States
NC Medial Research Inc

Recruiting

A Study of NCS-01 in Patients With Acute Ischemic Stroke

Ischemic Stroke

United States
IC-IT Sciences Inc.

Unknown

Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment

Sleep Disturbance

United States
F. Stephen Hodi, MD
MedImmune LLC

Completed

Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma

Metastatic Melanoma

United States
Viela Bio
MedImmune LLC

Completed

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc

United States
Terence Friedlander, MD
MedImmune LLC

Withdrawn

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

Bladder Cancer

United States
Zhengzhou Gensciences Inc
Haimen Gensciences lnc

Completed

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

Hemophilia A

China
Zhengzhou Gensciences Inc
Jiangsu Gensciences lnc.

Completed

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A (RH-107-III02)

Hemophilia A

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
MedImmune LLC

Completed

Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma

Myeloma

United States
Revimmune
Washington University School of Medicine; University Hospital, Limoges; George...

Terminated

Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients (IRIS-7-C&D)

Sepsis, Severe

United States, France
Shadia Jalal, MD
AstraZeneca; MedImmune LLC; Big Ten Cancer Research Consortium

Completed

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Esophageal Cancer

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

Influenza

Australia
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children

Respiratory Tract Infections

Spain, Israel
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial To Assess Safety And Efficacy Of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) In Adults Aged 60 Years And Older

Influenza

South Africa
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants

Healthy

Finland
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (FluMist)

Influenza

South Africa
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. (FluMist)

Influenza

Belgium, Poland, United Kingdom
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold- Adapted (CAIV-T) in Healthy Children Attending Day Care Centers

Influenza

Finland
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months

Influenza

Singapore

Clinical Trials Sponsored by Regimmune Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations